"3G" Trial: An RNA Editing Signature for Guiding Gastric Cancer Chemotherapy
Jimmy Bok-Yan So,
Sun Young Rha,
Lee Ming Hui,
Tay Su Ting,
Ong Xue Wen,
Angie Tan Lay Keng,
Matthew Chau Hsien Ng,
Wei Peng Yong,
Singapore Gastric Cancer Consortium (SGCC)
Posted 23 Jun 2020
bioRxiv DOI: 10.1101/2020.06.22.164038
Posted 23 Jun 2020
Background & Aims: Gastric cancer (GC) cases are often diagnosed at an advanced stage with poor prognosis. Platinum-based chemotherapy has been internationally accepted as first-line therapy for inoperable or metastatic GC. To achieve greater benefits, it is critical to select patients who are eligible for the treatment. Albeit gene expression profiling has been widely used as a genomic classifier to identify molecular subtypes of GC and stratify patients for different chemotherapy regimens, the prediction accuracy remains to be improved. More recently, adenosine-to-inosine (A-to-I) RNA editing has emerged as a new player contributing to GC development and progression, offering potential clinical utility for diagnosis and treatment. Methods: We conducted a transcriptome-wide RNA editing analysis of a cohort of 104 patients with advanced GC and identified an RNA editing (GCRE) signature to guide GC chemotherapy, using a systematic computational approach followed by both in vitro validations and in silico validations in TCGA. Results: We found that RNA editing events alone stand as a prognostic and predictive biomarker in advanced GC. We developed a GCRE score based on the GCRE signature consisting of 50 editing sites associated with 29 genes and achieved a high accuracy (84%) of predicting patient response to chemotherapy. Of note, patients demonstrating higher editing levels of this panel of sites present a better overall response. Consistently, GC cell lines with higher editing levels showed higher chemosensitivity. Applying the GCRE score on TCGA dataset confirmed that responders had significantly higher levels of editing in advanced GC. Conclusions: Overall, the GCRE signature reliably stratifies patients with advanced GC and predicts response from chemotherapy. ### Competing Interest Statement R.S. is an advisory board member of BMS, Merck, Eisai, Bayer, Taiho; and reports receiving honoraria for talks from MSD, Eli Lilly, BMS, Roche, Taiho and travel funding from Roche, Astra Zeneca, Taiho, Eisai and research funding from Paxman Coolers, MSD. P.T. reports receiving honoraria for travel from Illumina and research funding from Thermo Fisher, Kyowa Hakko Kirin. O.A. and L.C. are inventors in a patent application (10202003405Y) that is related to the work that is described in this manuscript. The other authors declare that they have no competing interest.
- Downloaded 191 times
- Download rankings, all-time:
- Site-wide: 103,459
- In cancer biology: 3,175
- Year to date:
- Site-wide: 56,327
- Since beginning of last month:
- Site-wide: 56,327
Downloads over time
Distribution of downloads per paper, site-wide
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!